259 related articles for article (PubMed ID: 15712070)
1. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C.
Muratori P; Muratori L; Guidi M; Granito A; Susca M; Lenzi M; Bianchi FB
Clin Infect Dis; 2005 Feb; 40(4):501-7. PubMed ID: 15712070
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of combination therapy with pegylated-interferon alfa-2a plus ribavirin in autoantibody-positive chronic hepatitis C patients].
Li YX; Yang YJ; Yang M; Chen LY; Lu JJ; Ma YJ; Liu K; Lei XZ; Tang H
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):345-7. PubMed ID: 24025134
[TBL] [Abstract][Full Text] [Related]
3. Non-organ-specific autoantibodies in children with chronic hepatitis C: clinical significance and impact on interferon treatment.
Muratori P; Muratori L; Verucchi G; Attard L; Bianchi FB; Lenzi M
Clin Infect Dis; 2003 Nov; 37(10):1320-6. PubMed ID: 14583865
[TBL] [Abstract][Full Text] [Related]
4. Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study.
Gatselis NK; Georgiadou SP; Tassopoulos N; Zachou K; Liaskos C; Hatzakis A; Dalekos GN
World J Gastroenterol; 2005 Jan; 11(4):482-7. PubMed ID: 15641130
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
[TBL] [Abstract][Full Text] [Related]
6. Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients.
Hsieh MY; Dai CY; Lee LP; Huang JF; Chuang WL; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Yu ML
Kaohsiung J Med Sci; 2012 Feb; 28(2):86-93. PubMed ID: 22313535
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C.
Chen CH; Lee CM; Chen CH; Hu TH; Wang JH; Hung CH; Chung CH; Lu SN
Chang Gung Med J; 2010; 33(3):258-65. PubMed ID: 20584503
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C.
Ferri S; Muratori L; Quarneti C; Muratori P; Menichella R; Pappas G; Granito A; Ballardini G; Bianchi FB; Lenzi M
J Hepatol; 2009 Jun; 50(6):1093-101. PubMed ID: 19398235
[TBL] [Abstract][Full Text] [Related]
9. Does an 'autoimmune' profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey.
Stroffolini T; Colloredo G; Gaeta GB; Sonzogni A; Angeletti S; Marignani M; Pasquale G; Venezia G; Craxì A; Almasio P
J Viral Hepat; 2004 May; 11(3):257-62. PubMed ID: 15117328
[TBL] [Abstract][Full Text] [Related]
10. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?
Narciso-Schiavon JL; Freire FC; Suarez MM; Ferrari MV; Scanhola GQ; Schiavon Lde L; de Carvalho Filho RJ; Ferraz ML; Silva AE
Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):440-6. PubMed ID: 19382301
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort.
Lenzi M; Bellentani S; Saccoccio G; Muratori P; Masutti F; Muratori L; Cassani F; Bianchi FB; Tiribelli C
Gut; 1999 Sep; 45(3):435-41. PubMed ID: 10446115
[TBL] [Abstract][Full Text] [Related]
13. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C.
Gatselis NK; Georgiadou SP; Koukoulis GK; Tassopoulos N; Zachou K; Liaskos C; Hatzakis A; Dalekos GN
Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1563-73. PubMed ID: 17094775
[TBL] [Abstract][Full Text] [Related]
15. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile.
Cassani F; Cataleta M; Valentini P; Muratori P; Giostra F; Francesconi R; Muratori L; Lenzi M; Bianchi G; Zauli D; Bianchi FB
Hepatology; 1997 Sep; 26(3):561-6. PubMed ID: 9303483
[TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
Covini G; Carcamo WC; Bredi E; von Mühlen CA; Colombo M; Chan EK
Antivir Ther; 2012; 17(5):805-11. PubMed ID: 22293655
[TBL] [Abstract][Full Text] [Related]
17. The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.
Monti V; Aghemo A; Rumi MG; Donato MF; Del Ninno E; Colombo M
Antivir Ther; 2005; 10(6):715-20. PubMed ID: 16218170
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility to thyroid disorders in hepatitis C.
Muratori L; Bogdanos DP; Muratori P; Lenzi M; Granito A; Ma Y; Mieli-Vergani G; Bianchi FB; Vergani D
Clin Gastroenterol Hepatol; 2005 Jun; 3(6):595-603. PubMed ID: 15952102
[TBL] [Abstract][Full Text] [Related]
19. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C.
Wasmuth HE; Stolte C; Geier A; Dietrich CG; Gartung C; Lorenzen J; Matern S; Lammert F
BMC Infect Dis; 2004 Feb; 4():4. PubMed ID: 15040810
[TBL] [Abstract][Full Text] [Related]
20. [Significance of non-organ-specific autoantibodies in HCV-related chronic hepatitis].
Guidi M; Muratori P; Granito A; Muratori L; Pappas G; Bianchi FB
Recenti Prog Med; 2005 Dec; 96(12):589-93. PubMed ID: 16496742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
